

---

# Amendment to **BULLETIN # 133**

---

## **Manitoba Drug Benefits and Manitoba Drug Interchangeability Formulary Amendments**

**The following amendments will take effect on  
August 27, 2024**

The amended Manitoba Drug Benefits Formulary and  
Manitoba Drug Interchangeability Formulary will be available  
on the Manitoba Health website  
<http://www.gov.mb.ca/health/mdbif> on the effective date of  
August 27, 2024

Bulletin 133 is currently available for download:  
<https://www.gov.mb.ca/health/mdbif/docs/bulletins/bulletin133.pdf>

<b>Inside This Issue</b>	
Part 1 Additions	Page 1
Exception Drug Status Additions	Page 1-2
New interchangeable Products	Page 2

## Part 1 Additions

DIN	TRADE NAME	GENERIC	STRENGTH	FORM	MFR*
00030759	<b>Depo-Medrol 40mg/mL</b>	methylprednisolone acetate	40 mg/mL	Injectable Suspension	PFI
01934333	<b>Depo-Medrol (with preservative) 40mg/mL</b>	methylprednisolone acetate	40 mg/mL	Injectable Suspension	PFI
00030767	<b>Depo-Medrol 80mg/mL</b>	methylprednisolone acetate	80 mg/mL	Injectable Suspension	PFI
01934341	<b>Depo-Medrol (with preservative) 80mg/mL</b>	methylprednisolone acetate	80 mg/mL	Injectable Suspension	PFI

\* Abbreviation of Manufacturers' Name

## Exception Drug Status Additions

02239630	<b>Tobi</b> <i>(updated criteria)</i>	tobramycin	60 mg/mL	Inhalation Solution	BGP
02389622	<b>Teva-Tobramycin</b> <i>(updated criteria)</i>	tobramycin	60 mg/mL	Inhalation Solution	TEV

For the treatment of chronic pulmonary pseudomonas infections in patients with cystic fibrosis (CF).

02371065 02457113	<b>Zytiga</b> <i>(new indication)</i>	abiraterone acetate	250 mg 500 mg	Tablets	JAN
02525380	<b>Abiraterone</b> <i>(new indication)</i>	abiraterone acetate	500 mg	Tablets	JPC
02491397 02491400	<b>Apo-Abiraterone</b> <i>(new indication)</i>	abiraterone acetate	250 mg 500 mg	Tablets	APX
02502305 02529629	<b>Jamp Abiraterone</b> <i>(new indication)</i>	abiraterone acetate	250 mg 500 mg	Tablets	JPC
02503980 02503999	<b>Mar-Abiraterone</b> <i>(new indication)</i>	abiraterone acetate	250 mg 500 mg	Tablets	MAR
02494132	<b>Nat-Abiraterone</b> <i>(new indication)</i>	abiraterone acetate	250 mg	Tablets	NAT
02492601 02501503	<b>pms-Abiraterone</b> <i>(new indication)</i>	abiraterone acetate	250 mg 500 mg	Tablets	PMS
02477114 02533251	<b>Reddy-Abiraterone</b> <i>(new indication)</i>	abiraterone acetate	250 mg 500 mg	Tablets	DRL
02486393 02521644	<b>Sandoz-Abiraterone</b> <i>(new indication)</i>	abiraterone acetate	250 mg 500 mg	Tablets	SDZ

Abiraterone and prednisone in combination with docetaxel, for the treatment of patients:

- With metastatic castration-sensitive prostate cancer (mCSPC) AND

- Who are eligible for chemotherapy AND
- With good performance status AND
- With prior bilateral orchiectomy or currently receiving Androgen Deprivation Therapy (ADT) with a gonadotropin-releasing hormone (GnRH)/luteinizing hormone releasing hormone (LHRH) agonist or antagonist

Exclusion criteria:

- Prior treatment with an androgen receptor pathway inhibitor (ARPI), chemotherapy or immunotherapy for prostate cancer
- Received androgen deprivation therapy in the metastatic setting for more than 6 months or within 1 year of completing adjuvant ADT in the non-metastatic setting

---

## New Interchangeable Products

---

The following products have been added to existing interchangeable drug categories:

<b>Rizatriptan - 10 mg - Orally Disintegrating Tablets</b>				<b>\$</b>	<b>\$ + 5%</b>
02489384	NRA-Rizatriptan ODT	NRA	3.7050	3.8903	

  

<b>Zolmitriptan - 2.5 mg - Tablets</b>				<b>\$</b>	<b>\$ + 5%</b>
02489392	NRA-Zolmitriptan	NRA	3.5375	3.7144	